title: Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer.
abstract: BACKGROUND
  Tissue inhibitor of metalloproteinase 1 (TIMP-1) is a natural inhibitor of the matrix metalloproteinases (MMPs) which are proteolytic enzymes involved in degradation of extracellular matrix thereby favoring tumour cell invasion and metastasis. TIMP-1 activity in tumour tissue may therefore play an essential role in the progression of a malignant tumour.The primary aim of the present study was to evaluate TIMP-1 protein immunoreactivity in tissue from primary ovarian cancer patients and associate these findings with the course of the disease including response to treatment in the individual patient.
  
  
  METHODS
  TIMP-1 was assessed by immunohistochemistry (in tissue micro arrays) in a total of 163 ovarian cancer specimens obtained from primary debulking surgery during 1991-1994 as part of a randomized clinical protocol.
  
  
  RESULTS
  Positive TIMP-1 immunoreactivity was found in 12.3% of the tumours. The median survival time for the 143 patients with TIMP-1 negative tumours was 23.7 months [19.0-29.4] 95% CI, while the median survival time for the 20 patients with TIMP-1 positive tumours was 15.9 months [12.3-27.4] 95% CI. Although a difference of 7.8 months in median overall survival in favor of the TIMP-1 tumour negative patients was found, this difference did not reach statistical significance (p = 0.28, Kaplan-Meier, log-rank test). Moreover, TIMP-1 immunoreactivity was not associated with CA125 response (p = 0.53) or response at second look surgery (p = 0.72).
  
  
  CONCLUSIONS
  TIMP-1 immunoreactivity in tumour tissue from patients with primary epithelial ovarian cancer did not correlate with patient survival or response to combination platinum/cyclophosphamide therapy.
authors.affiliation: Department of Oncology, Vejle Hospital, Kabbeltoft 25, DK-7100 Vejle, Denmark. Karina.Dahl.Steffensen@slb.regionsyddanmark.dk
authors.forename: Karina Dahl
authors.initials: KD
authors.lastname: Steffensen
authors.forename: Marianne
authors.initials: M
authors.lastname: Waldstrøm
authors.forename: Rikke Kølby
authors.initials: RK
authors.lastname: Christensen
authors.forename: Annette
authors.initials: A
authors.lastname: Bartels
authors.forename: Nils
authors.initials: N
authors.lastname: Brünner
authors.forename: Anders
authors.initials: A
authors.lastname: Jakobsen
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018394:CA-125 Antigen / Q000097:blood; D016190:Carboplatin / Q000008:administration & dosage; D002277:Carcinoma / Q000737:chemistry* / Q000401:mortality / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D013509:Gynecologic Surgical Procedures; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008565:Membrane Proteins / Q000097:blood; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000737:chemistry* / Q000473:pathology / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic; D024162:Second-Look Surgery; D013997:Time Factors; D046888:Tissue Array Analysis / Q000379:methods*; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000032:analysis*; D016896:Treatment Outcome
chemical_list: D018394:CA-125 Antigen; C451759:MUC16 protein, human; D008565:Membrane Proteins; D019715:Tissue Inhibitor of Metalloproteinase-1; D003520:Cyclophosphamide; D016190:Carboplatin
references.citation: Tumour Biol. 2008;29(3):181-7
references.pmid: 18645261
references.citation: Gynecol Oncol. 2005 Dec;99(3):656-63
references.pmid: 16112717
references.citation: J Natl Cancer Inst. 2004 Mar 17;96(6):487-8
references.pmid: 15026475
references.citation: J Invest Dermatol. 1991 Oct;97(4):679-85
references.pmid: 1940438
references.citation: Cancer. 2005 Apr 15;103(8):1676-84
references.pmid: 15754326
references.citation: Mol Hum Reprod. 2003 Oct;9(10):569-75
references.pmid: 12970394
references.citation: Anticancer Res. 2007 Jul-Aug;27(4C):2753-8
references.pmid: 17695443
references.citation: J Clin Oncol. 2003 May 15;21(10 Suppl):187s-193s
references.pmid: 12743133
references.citation: Int J Oncol. 2000 Oct;17(4):673-81
references.pmid: 10995877
references.citation: J Biol Chem. 2003 Oct 10;278(41):40364-72
references.pmid: 12904305
references.citation: Clin Cancer Res. 2001 Oct;7(10):3113-9
references.pmid: 11595703
references.citation: Br J Cancer. 1997;76(4):531-6
references.pmid: 9275032
references.citation: Eur J Cancer. 2009 Sep;45(14):2528-36
references.pmid: 19535243
references.citation: Scand J Gastroenterol. 2008;43(2):186-91
references.pmid: 18224564
references.citation: J Histochem Cytochem. 2006 Oct;54(10):1075-86
references.pmid: 16517973
references.citation: Dig Dis Sci. 2000 Jan;45(1):114-21
references.pmid: 10695623
references.citation: Int J Cancer. 1999 Feb 19;84(1):44-8
references.pmid: 9988231
references.citation: Gynecol Oncol. 2005 Sep;98(3):520-1
references.pmid: 15913743
references.citation: Scand J Gastroenterol. 2008;43(7):774-86
references.pmid: 18584515
references.citation: J Clin Oncol. 1997 Jan;15(1):193-8
references.pmid: 8996142
references.citation: J Clin Invest. 1998 Dec 1;102(11):2002-10
references.pmid: 9835626
references.citation: Gynecol Oncol. 2000 Jun;77(3):369-76
references.pmid: 10831344
references.citation: Clin Cancer Res. 2007 Jul 15;13(14):4117-22
references.pmid: 17634538
references.citation: Clin Cancer Res. 1996 Aug;2(8):1369-72
references.pmid: 9816309
references.citation: Clin Cancer Res. 2006 Dec 1;12(23):7054-8
references.pmid: 17114213
references.citation: Int J Oncol. 2008 Dec;33(6):1239-46
references.pmid: 19020757
references.citation: Cancer. 1998 Mar 1;82(5):893-901
references.pmid: 9486579
references.citation: Cancer Lett. 1997 Nov 25;120(1):109-15
references.pmid: 9570393
references.citation: Blood. 1995 Dec 15;86(12):4506-15
references.pmid: 8541540
references.citation: Eur J Cancer. 2003 Sep;39(13):1948-56
references.pmid: 12932675
references.citation: Int J Cancer. 2000 Nov 15;88(4):575-8
references.pmid: 11058873
references.citation: Cancer Res. 1999 Dec 15;59(24):6267-75
references.pmid: 10626822
references.citation: BMC Cancer. 2009 Sep 10;9:322
references.pmid: 19744322